McCormick-Unilever Food Deal Faces UK Competition Review: What it Means for Investors

The UK Competition and Markets Authority (CMA) has opened a Phase 1 investigation into the proposed $65 billion merger between McCormick & Company, Incorporated (NYSE:MKC) and Unilever PLC (NYSE:UL)’s food business, assessing whether the transaction could reduce competition in UK food markets. The CMA has set November 11, 2026, as the deadline for its initial decision. If the regulator finds competition concerns, the transaction could face a deeper Phase 2 review or potential remedies.

The transaction would combine McCormick’s spices and sauces with Unilever brands including Knorr, Hellmann’s, French’s and Frank’s RedHot. Unilever and its shareholders are expected to own 65% of the combined company, while McCormick shareholders would hold 35%. The deal values Unilever’s food business at nearly $45 billion and McCormick at about $21 billion.

McCormick and Unilever Can Still Unlock Significant Scale From the Deal

For McCormick & Company, Incorporated, regulatory scrutiny does not necessarily undermine the strategic rationale of the transaction. Reuters previously described the deal as potentially transformational for McCormick because it would provide substantially greater global scale and distribution, particularly in condiments. Combining McCormick’s spice portfolio with Unilever’s large food brands could also create greater purchasing, manufacturing and distribution efficiencies over time.

The transaction could also give McCormick exposure to a much larger international revenue base. Unilever’s food business generated nearly €13 billion of revenue in 2025, representing more than one-quarter of Unilever’s €50 billion of total revenue, with 53% of food sales coming from emerging markets. That geographic reach could materially expand McCormick’s competitive footprint if the merger receives regulatory approval without major remedies.

For Unilever PLC, completing the transaction would advance its strategy of becoming more focused on beauty, personal care and home products. Reuters reported in August that Unilever trades at 11.5 times enterprise value to core earnings, below multiples of 14.8 times for Procter & Gamble and 17.5 times for L’Oréal. Management is therefore seeking to demonstrate that a more focused portfolio can improve its valuation.

The CMA Investigation Puts the Deal’s Strategic Benefits Under Pressure

The CMA review introduces additional execution risk into a transaction already worth $65 billion. A prolonged investigation could delay closing, increase advisory and integration costs, and potentially require asset sales or other remedies that reduce the expected strategic benefits. The November 11 Phase 1 deadline means investors will have to wait for greater regulatory clarity before the deal’s path becomes clearer.

For McCormick & Company, Incorporated, regulatory concessions could weaken the scale benefits that underpin the transaction. The company is effectively using the deal to transform itself through a combination with a food business valued at nearly $45 billion, more than twice the approximately $21 billion valuation assigned to McCormick. Any forced divestitures in overlapping UK categories could therefore reduce the geographic or brand advantages expected from the combination.

Unilever PLC also faces the risk that the review delays its portfolio simplification. Food accounted for nearly €13 billion of revenue in 2025, and Reuters has noted that the business remains relatively high margin even though its sales growth has lagged beauty and personal care. A delayed separation would leave Unilever exposed to the slower-growth food category for longer while postponing the expected benefits of its strategic refocus.

Conclusion

The CMA investigation creates a new regulatory hurdle but does not, by itself, change the underlying strategic logic of the transaction. McCormick & Company, Incorporated stands to gain substantial scale and international distribution from Unilever’s €13 billion food business, while Unilever PLC would receive $15.7 billion in cash and continue its shift toward higher-growth consumer categories. The key near-term issue is whether UK competition concerns lead to remedies that materially reduce those benefits or delay completion beyond the companies’ expectations.

READ NEXT: Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity and Boeing (BA) Strengthens its Backlog with Korean Air’s 103-Aircraft Commitment

This article is originally published at Insider Monkey.